// App-Quantinova.ai

TPS6591 : INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Researchers

Presenter

  • Aaron Richard Hansen

Principal Investigators

  • Thomas S. Stanton

  • Min Hee Hong

  • Ezra E.W. Cohen

  • Hisham Mohamed Mehanna

  • Michael Jon Chisamore

  • David Turner

  • Sapna Yadavilli

  • Kelly Bell

  • Carlos Baccan

  • Rosalida Leone

  • Helen Chen

  • Helen Zhou

  • Catherine Elizabeth Ellis

  • Marc S. Ballas

  • Axel Hoos

  • Danny Rischin

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • St Joseph Hospital, Santa Rosa, CA

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Institute of Head and Neck Studies and Education, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

  • Merck and Co., Kenilworth, NJ

  • GlaxoSmithKline, Collegeville, PA

  • GlaxoSmithKline, Collegeville, Upper Providence, PA

  • GlaxoSmithKline, Stockley Park, United Kingdom

  • GlaxoSmithKline, Upper Providence, PA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Adaptive

  • Double Blind/Blinded

  • Superiority

Phase

  • NA

Study Id's

  • NCT04128696

Sponsors

  • GlaxoSmithKline(GSK) And Merck Sharp & Dohme (MSD)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved